{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-062046","form_type":"8-K","ticker":"ANTX","cik":"0001880438","company_name":"AN2 Therapeutics, Inc.","filed_at":"2023-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.260859+00:00","generated_at":"2026-06-08T07:48:18.231322+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"AN2 Therapeutics Q3 net loss $16.7M; epetraborole Phase 3 enrollment underway","bullets":["Net loss $16.7M for Q3 2023, up from $11.3M in Q3 2022; R&D and G&A expenses increased.","Cash and investments $150.2M at Sept 30; $70M raised in August stock offering; cash runway through summer 2025.","Phase 3 part of pivotal epetraborole trial in refractory MAC lung disease initiated; Phase 2 top-line data expected summer 2024.","Received Bill & Melinda Gates Foundation grant for TB/malaria; exclusive license for Chagas disease candidate AN2-502998."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-062046","json":"https://secwatch.observer/filing/0000950170-23-062046.json","markdown":"https://secwatch.observer/filing/0000950170-23-062046.md","text":"https://secwatch.observer/filing/0000950170-23-062046.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1880438/000095017023062046/0000950170-23-062046-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1880438/000095017023062046/antx-20231109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T07:48:18.231322+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c425037437eb32c12637d01ac0e1b89767c7a1f4","claim":"AN2 Therapeutics, Inc. reported third quarter ended September 30, 2023 results: net income Net loss was $16.7 million.","evidence_excerpt":"On November 9, 2023, AN2 Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1880438/000095017023062046/0000950170-23-062046-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2023"},{"label":"Net income","value":"Net loss was $16.7 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}